Applicated value of rosuvastatin in the treatment of coronary heart disease patients with diabetes
10.3760/cma.j.issn.1008-6706.2014.09.026
- VernacularTitle:瑞舒伐他汀在冠心病合并糖尿病治疗中的应用价值
- Author:
Shengzhi WU
;
Xiaoke SHI
;
Ruopei ZHU
;
Yifei CHEN
;
Feixue LIAO
- Publication Type:Journal Article
- Keywords:
statin;
coronary heart disease;
diametes;
LDL-C;
hs-CRP
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;(9):1334-1335
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare main adverse cardiac events of patients with coronary heart disease and diametes,but normal lipids after statin on lowering lipids , and to bring out necessity of early lowering lipids . Methods A total of 324 patients with coronary heart disease and diametes were enrolled ,LDL-C was measured in-hospital for all patients and LDL-C<3.36mmol/L suitable for the experiment .They were divided into statin group (n=176,rosuvastatin 10 mg/d)and control group(n=148)randomly,all patients received second prevention for cor-onary heart disease including anti-platelet,anti-myocardial ischemia,smoke quitting,adjust diets and exercise,the CAG or PTCA(and stent implanting),CABG.the end events were main adverse cardiac events (cardiac events,recur-rent angina and target vessel reconstruction ).The mean follow-up time was(13 ±6)months.Results The fasting plasma glucose,LDL-C,hs-CRP in statin group were all significantly lower than those of control group [FPG:(5.3 ± 0.9)vs.(6.7 ±1.2)mmol/L,P=0.042;LDL-C:(1.7 ±0.6)mmol/Lvs.(3.9 ±1.6)mmol/L,P<0.01;hs-CRP:(1.4 ±0.5)mmol/L vs.(3.8 ±1.2)mg/L,P <0.01],MACE were less(15.6% vs.37.1%,P =0.032). Conclusion Early statin on patient with coronary heart disease and diametes ,though normal lipids ,which can down-regulate main adverse cardiac events significantly .
